LOAN HO: Open Payments
NPI 1568895274 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,063 in 86 payments from 12 companies in 2025. Trend: 2023 $1,899 · 2024 $2,051 · 2025 $2,063
Food & beverage: $1,973Education: $90
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $500 |
| Gilead Sciences, Inc. | 17 | $422 |
| Madrigal Pharmaceuticals | 11 | $339 |
| ABBVIE INC. | 13 | $264 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $165 |
| Intercept Pharmaceuticals, Inc. | 5 | $93 |
| Organon LLC | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Becton, Dickinson and Company | 1 | $59 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
Products named: TREMFYA, REZDIFFRA, XIFAXAN, SKYRIZI, Livdelzi, OCALIVA, HADLIMA, RINVOQ.
Industry payments across TX — which companies pay providers there.
